| Detected | Trial | Change |
|---|---|---|
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Recruitment opened |
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Enrollment increased: 30 -> 92 participants |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Recruitment opened |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Enrollment increased: 100 -> 110 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Ph+ ALL | Recruiting |
| Phase 2 | |||
| NCT06817720 | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in… | Chronic Myeloid Leukemia | Recruiting |
| NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in… | Phase II Clinical Trial | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients… | Relapsed/Refractory Acute Myeloid Leukaemia | Recruiting |
| Phase 1 | |||
| NCT06401603 | A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced… | Advanced Chronic Myeloid Leukemia | Recruiting |
| Not specified | |||
| NCT06481228 | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND… | Philadelphia Positive Acute Lymphoblastic Leukemia | Recruiting |
| NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | Ph-Like | Recruiting |
| NCT07493161 | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | Ph+ ALL | Recruiting |
| NCT07383298 | Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic… | Chronic Myeloid Leukemia | Enrolling by Invitation |